CYMBALTA

LOE Approaching

duloxetine hydrochloride

Eli Lilly and Company
NDAORALCAPSULE, DELAYED REL PELLETS
Approved
Aug 2004
Lifecycle
LOE Approaching
Competitive Pressure
30/100
Clinical Trials
106

Mechanism of Action

antidepressant, central pain inhibitory and anxiolytic actions of duloxetine in humans are unknown, these actions are believed to be related to its potentiation of serotonergic and noradrenergic activity in the CNS.

Indications (4)

the following conditions: Major depressive disorder (MDD) in adults () Generalized anxiety disorder (GAD) in adultsolder () Diabetic peripheral neuropathic pain (DPNP) in adults () Fibromyalgia (FM) in adultsolder () Chronic musculoskeletal pain in adults ()anxiety

Clinical Trials (5)

NCT03794154Phase 4Withdrawn

A Study Of Duloxetine Hydrochloride Hard Gelatinous Capsule Compared To Cymbalta Under Fed Conditions

Started Mar 2020
0
Healthy
NCT03729284Phase 4Withdrawn

A Study of Duloxetine Hydrochloride Hard Gelatinous Capsule Compared To Cymbalta

Started Mar 2020
0
Healthy
NCT03395353Phase 3Terminated

A Study of Duloxetine (LY248686) in the Treatment of Japanese Children and Adolescents With Depressive Disorder

Started Jan 2018
151 enrolled
Depressive Disorder
NCT03315793Phase 3Completed

A Study of Duloxetine (LY248686) in Japanese Children and Adolescents With Depressive Disorder

Started Dec 2017
149 enrolled
Depressive Disorder
NCT02417935Phase 4Completed

A Study of Duloxetine (LY248686) in Participants With Diabetic Peripheral Neuropathic Pain (DPNP)

Started Apr 2015
304 enrolled
Diabetic Peripheral Neuropathic Pain
Company
Eli Lilly and Company
Eli Lilly and Company
INDIANAPOLIS, IN
838 open jobs
External Resources
DailyMed
Full prescribing information
FDA Drugs@FDA
FDA approval history
RxNorm
Drug nomenclature & identifiers